SEARCH

SEARCH BY CITATION

Additional supporting information may be found in the online version of this article:

FilenameFormatSizeDescription
pds_2136_sm_t1.docWord document52KSupplementary Table 1. Higher level terms and preferred terms for special adverse events
pds_2136_sm_t2.docWord document61KSupplementary Table 2. Preferred terms used to identify neuropsychiatric adverse events
pds_2136_sm_t3.docWord document40KSupplementary Table 3. Preferred terms used to identify immunocompromised status
pds_2136_sm_t6.docWord document48KSupplementary Table 4. List of medications used to identify immunocompromised status
pds_2136_sm_t7.docWord document41KSupplementary Table 5. Confounding factors in patients exposed to oseltamivir who had fatal serious adverse events. Some patients had more than one confounding factor
pds_2136_sm_t8.docWord document35KSupplementary Table 6. Case descriptions of five patients with fatal adverse events where no confounding factors (see Supplementary Table 5) were present

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.